United Kingdom Pharmaceuticals and Healthcare Report Q2 2011

The United Kingdom Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)’s 5 and 10-year forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI’s United Kingdom Pharmaceuticals & Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the British pharmaceutical and healthcare industry.

Key Benefits

- Benchmark BMI’s independent 5 and 10-year pharmaceutical and healthcare industry forecasts on United Kingdom to test other views – a key input for successful budgeting and strategic business planning in the British pharmaceutical and healthcare market.
- Target business opportunities and risks in the British pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in United Kingdom.
- Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs, latest activity) and Competitive Landscape Tables.

Coverage:

Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTS, give a complete overview of market climate.

Market Summary
Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation, advertising, as well as an analysis of the overall regulatory burden.

Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI 5 and 10-Year Industry Forecast
5 and 10-year forecasts for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per ‘000 population), doctors (per ‘000 population), birth and mortality rate (per ‘000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape
Competitive landscape provides comparative company analyses and rankings by US$ sales, % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles
Examining the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT (Strengths, Weaknesses, Opportunities and Threats) analyses. Latest financial and operating statistics and key company developments are also incorporated within our company profiles, enabling a full evaluation of recent company performance and future growth prospects. SHOW LESS READ MORE >

SWOT Analysis
UK Pharmaceuticals And Healthcare Industry SWOT
UK Political SWOT
UK Economic SWOT

Pharmaceutical Business Environment Ratings
Table: Western Europe Pharmaceuticals Business Environment Ratings For Q211
Risks

UK – Market Summary
Regulatory Regime
Regulatory Developments
Innovative Medicines
Generic Medicines
OTC Medicines
Intellectual Property Issues
Counterfeit Pharmaceuticals
Table: Examples Of Recalls Of Counterfeit Medicines In The UK
Pricing Regime
Table: Bilateral Comparisons For Ex-Manufacturer Prices*
Generic Drug Prices
OTC Prices
Reimbursement Regime

Industry Developments
Epidemiology
Non-Communicable Disease
Communicable Diseases
Healthcare Sector
Healthcare Financing
Health Insurance
Health Tourism
Wholesale Sector
Wholesale Sector Developments
Retail Sector

UK Registered Retail Pharmacies As Of March 2008
Parallel Imports
Research & Development
Biotechnology
Clinical Trials
Industry Forecast Scenario
Overall Market Forecast
Table: Pharmaceutical Sales Indicators 2007-2015

Key Growth Factors – Industry
Table: Healthcare Expenditure Indicators 2007-2015
Table: Government Healthcare Expenditure Indicators 2007-2015
Table: Private Healthcare Expenditure Indicators 2007-2015

Key Growth Factors – Macroeconomic
Table: United Kingdom – Economic Activity, 2007-2015
Prescription Drug Market Forecast
Table: Prescription Drug Sales Indicators 2007-2015
Patented Drug Market Forecast
Table: Patented Drug Market Indicators 2007-2015
Generic Drug Market Forecast
Table: Generic Drug Sales Indicators 2007-2015

OTC Medicine Market Forecast
Table: OTC Medicine Sales Indicators 2007-2015
Pharmaceutical Trade Forecast
Table: Exports and Imports Indicators 2007-2015

Medical Device Market Forecast
Key Risks to BMI Forecasts
Competitive Landscape
Pharmaceutical Industry
Top 20 UK-Based Pharmaceutical Companies According To Market Capitalisation
Top 20 UK-Based Biotechnology Companies According To Market Capitalisation

Company Developments
Table: Leading Pharmaceutical Corporations In The UK By Market Share (2007)
Table: Top Pharmaceutical Products In The UK (2007)
Table: Cost Of Prescriptions* Dispensed In Various Disease Areas, 1995-2006 (GBPmn)

Company Profiles

Leading Indigenous Manufacturers
GlaxoSmithKline
AstraZeneca

Leading Multinational Manufacturers
Pfizer
Novartis
Sanofi-Aventis
Merck & Co

Country Snapshot: UK Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education and Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market and Spending Power
Table: Employment Indicators, 2000-2005
Table: Consumer Expenditure, 2000-2011 (US$)
Table: Average Annual Wages, 2000-2012

BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Risk/Reward Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components

- GlaxoSmithKline
- AstraZeneca
- Pfizer
- Novartis
- Sanofi-Aventis
- Merck & Co